Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period
Annals of the Rheumatic DiseasesPublished 4 November 2014Open access
Paul Emery, Gerd R Burmester, Vivian P. Bykerk, Bernard Combe, Daniel E. Fürst, Emilie Barré
Citations232
SJR quartileQ1
SJR score5.73
SNIP4.44
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
The achievement of sustained remission following withdrawal of all RA therapy suggests an effect of abatacept's mechanism on autoimmune processes, as well as a safety profile comparable with MTX alone.
Abstract
NCT01142726.
Keywords
Medicine
Arthritis Care & Research2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis
1,792 Citations2012Jasvinder A. Singh, Daniel E. Fürst +28 more
The 2012 ACR RA recommendations were developed by two expert panels: a non-voting working group and Core Expert Panel of clinicians and methodologists responsible for the selection of the relevant topic areas to be considered, the systematic literature review, and the evidence synthesis.
Arthritis & RheumatismAmerican College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials
1,019 Citations2011David T. Felson, Josef S Smolen +42 more
This work proposes two new definitions of remission that can be uniformly applied and widely used in RA clinical trials, and recommends that one of these be selected as an outcome measure in each trial and that the results on both be reported for each trial.
Annals of the Rheumatic DiseasesAmerican College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials
771 Citations2011David T. Felson, Josef S Smolen +42 more
It is proposed that a patient's RA can be defined as being in remission based on one of two definitions: (1) when scores on the tender joint count, swollen joint counts, CRP level, and patient global assessment are all ≤1, or (2) when the score on the Simplified Disease Activity Index is ≤3.
Arthritis & RheumatismThe prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis
635 Citations2000E. J. A. Kroot, B.A.W. de Jong +8 more
The data show that in almost 70% of RA patients, anti-CCP antibody is present at the early stages of disease, and patients with anti- CCP-positive patients developed significantly more severe radiologic damage than patients who were anti- CCP negative.
Arthritis & RheumatismVery early treatment with infliximab in addition to methotrexate in early, poor‐prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twelve‐month randomized, double‐blind, placebo‐controlled trial
533 Citations2005Mark Quinn, Philip G. Conaghan +8 more
Remission induction with infliximab plus MTX provided a significant reduction in MRI evidence of synovitis and erosions at 1 year, and functional and quality of life benefits were sustained, despite withdrawal of inflIXimab therapy, which may have significant implications for the optimal use of expensive biologic therapies.
PubMedICH Harmonised Tripartite Guideline: Guideline for Good Clinical Practice.
531 Citations2002P. S. Bhuiyan, N. N. Rege
British journal of rheumatologyRemission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria
474 Citations2004Jaap Fransen
The optimal cut-off point for the DAS28 that corresponds to fulfilment of the preliminary ARA criteria for clinical remission in RA was determined to be 2.66.
Arthritis & RheumatismCostimulatory blockade in patients with rheumatoid arthritis: A pilot, dose‐finding, double‐blind, placebo‐controlled clinical trial evaluating CTLA‐4Ig and LEA29Y eighty‐five days after the first infusion
384 Citations2002Larry W. Moreland, Rieke Alten +9 more
Both CTLA-4Ig and LEA29Y demonstrated efficacy in the treatment of RA, and were generally safe and well tolerated.
The LancetMaintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial
347 Citations2013Josef S Smolen, Peter Nash +12 more
Conventional or reduced doses of etanercept with methotrexate in patients with moderately active rheumatoid arthritis more effectively maintain low disease activity than does methotRexate alone after withdrawal of etAnercept.
Annals of the Rheumatic DiseasesClinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors
346 Citations2009René Westhovens, M. Robles +15 more
In a methotrexate-naive population with early RA and poor prognostic factors, the combination of abatacept and methotRexate provided significantly better clinical and radiographic efficacy compared with methot Rexate alone and had a comparable, favourable safety profile.
The LancetAdjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial
272 Citations2013Josef S Smolen, Paul Emery +9 more
Treatment to a stable low disease activity target resulted in improved clinical, functional, and structural outcomes, with both adalimumab-continuation and methotrexate-monotherapy.
Annals of the Rheumatic DiseasesImpact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial)
253 Citations2009P. Emery, Patrick Durez +10 more
Abatacept delayed progression of UA/very early RA in some patients and an impact on radiographic and MRI inhibition was seen, which suggests that it is possible to alter the progression of RA by modulating T-cell responses at a very early stage of disease.
Diabetes CareCostimulation Modulation With Abatacept in Patients With Recent-Onset Type 1 Diabetes: Follow-up 1 Year After Cessation of Treatment
204 Citations2013Tihamer Orban, Brian N. Bundy +18 more
The beneficial effect of costimulation modulation with abatacept slowed decline of β-cell function and improved HbA1c in recent-onset T1D.
Annals of the Rheumatic DiseasesInduction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naïve patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study
186 Citations2012J. Detert, H. Bastian +16 more
A greater reduction in radiographic progression after initial combination therapy with ADA and MTX was seen at week 48, even after discontinuation of ADA treatment at week 24, while a sustained effect was not found at the primary outcome (DAS28 reduction).
Arthritis & RheumatismPrognostic markers of radiographic progression in early rheumatoid arthritis
168 Citations2004Jörg J. Goronzy, Eric L. Matteson +13 more
Clinical disease activity in patients with early RA can frequently be controlled with nonaggressive treatment, but this is not always sufficient to prevent new erosions and a polymorphism in the uteroglobin gene may identify patients who have a low risk of erosive disease.
Annals of the Rheumatic DiseasesRemission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study)
163 Citations2013J. Nam, Édith Villeneuve +14 more
In DMARD-naive early RA patients, initial therapy with MTX+high-dose intravenous steroid resulted in good disease control with little structural damage andMTX+IFX was not statistically superior to MTX +intravenous steroid when combined with a treat-to-target approach.
PubMedEarly rheumatoid arthritis -- is there a window of opportunity?
142 Citations2007John J. Cush
Rheumatologists should rise to the challenge and educate clinicians about this window of opportunity, the potential for remission, and superior clinical responses when patients with early RA or undifferentiated arthritis are referred to and managed by experts in aggressive rheumatologic care.
PubMedGood clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study.
142 Citations2007Luana Mancarella, Francesca Bobbio‐Pallavicini +25 more
It is shown that only a minority of patients with longstanding RA achieve a good clinical response or remission at the outpatient community level and predictors of remission identify characteristics commonly observed in subsets with less severe RA.
Annals of the Rheumatic DiseasesBiologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis
134 Citations2013Paul Emery, Anthony Sebba +1 more
Only for tocilizumab is there evidence that the efficacy of biologic monotherapy is comparable with combination therapy with MTX, and real-life registry data reveal approximately one-third of patients taking biologic agents use them as monotherapy.
Annals of the Rheumatic DiseasesDiscontinuation of infliximab and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and disease activity score-steered therapy: subanalysis of the BeSt study
124 Citations2011Maries van den Broek, Naomi B. Klarenbeek +7 more
The disease course after the cessation of infliximab in early rheumatoid arthritis patients with disease activity score (DAS)-steered treatment and to identify predictors of persistent low disease activity was described and smoking, long inflixIMab treatment duration and SE were independently associated with re-introduction of inflIXimab.
Modern RheumatologyDrug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study
119 Citations2013Norihiro Nishimoto, Koichi Amano +24 more
TCZ monotherapy may induce biologics-free remission or LDA without concomitant use of synthetic DMARDs and Serum levels of IL-6 and MMP-3 are useful markers for identifying patients who could discontinue TCZ without acute disease flare.
Annals of the Rheumatic DiseasesClinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study
110 Citations2014T. Huizinga, Philip G. Conaghan +8 more
Treat-to-target strategies could be successfully implemented with TCZ to achieve sustained remission, after which TCZ was stopped.
Arthritis Care & ResearchClinical remission and/or minimal disease activity in patients receiving adalimumab treatment in a multinational, open‐label, twelve‐week study
109 Citations2007Gerd R Burmester, Gianfranco Ferraccioli +5 more
This analysis represents the largest prospective clinical trial data set to be assessed using Outcome Measures in Rheumatology Clinical Trials MDA criteria and 25% of patients experienced clinical remission and nearly half achieved MDA.
Best Practice & Research Clinical RheumatologyProgression in early rheumatoid arthritis
97 Citations2009Bernard Combe
Intensive treatment such as combination DMARDs plus steroids or mainly biological therapies can induce high rates of remission and control of radiological progression, and can provide better outcomes than DMARD monotherapy in early RA, and should be considered very early in at-risk patients.
Autoimmunity ReviewsAdvances in CTLA-4-Ig-mediated modulation of inflammatory cell and immune response activation in rheumatoid arthritis
89 Citations2013Maurizio Cutolo, Steven G. Nadler
An overview of recent mechanistic studies of the action of CTLA-4-Ig on different cell types involved in mediating inflammation and joint damage in RA is provided.
Arthritis & RheumatismMacrophage migration inhibitory factor regulates neutrophil chemotactic responses in inflammatory arthritis in mice
86 Citations2010Leilani L. Santos, Huapeng Fan +7 more
It is suggested that MIF promotes neutrophil trafficking in inflammatory arthritis via facilitation of chemokine-induced migratory responses and MAP kinase activation.
Arthritis Care & ResearchImmunogenicity, Safety, and Efficacy of Abatacept Administered Subcutaneously With or Without Background Methotrexate in Patients With Rheumatoid Arthritis: Results From a Phase III, International, Multicenter, Parallel‐Arm, Open‐Label Study
71 Citations2012Peter Nash, S. Nayiager +9 more
To evaluate the impact of concomitant methotrexate (MTX) on subcutaneous (SC) abatacept immunogenicity, and to assess safety and efficacy.
Arthritis Care & ResearchGreater likelihood of remission in rheumatoid arthritis patients treated earlier in the disease course: Results from the Consortium of Rheumatology Researchers of North America registry
68 Citations2011Daniel E. Fürst, Aileen L. Pangan +5 more
To examine whether disease duration is an independent predictor of achieving remission in rheumatoid arthritis patients initiating therapy, a large number of patients initiate therapy with a history of disease duration at least a year before starting therapy.
Clinical RheumatologyA predictive model for remission and low disease activity in patients with established rheumatoid arthritis receiving TNF blockers
19 Citations2013Cristina Pomîrleanu, Codrina Ancuța +2 more
A predictive matrix for remission and LDA in established active RA patients receiving TNF-α inhibitors was proposed and further studies are necessary to confirm the value of such matrix in particular RA settings, leading to optimization of the use of anti-TNF- α therapy.
Annals of the Rheumatic DiseasesSAT0255 Clinical and Radiographic Outcomes at 2 Years and the Effect of TOCILIZUMAB Discontinuation following Sustained Remission in the Second and Third Year of the ACT-RAY Study
4 Citations2014T. Huizinga, Philip G. Conaghan +8 more
Efficacy and safety of TCZ-based treatment strategies were comparable, but small differences favored combination therapy, and T2T strategies could be successfully implemented with TCZ to achieve sustained remission.